# Blue Ox Healthcare Partners

> Blue Ox Healthcare Partners is a VC fund backing Health Care and Biotechnology. See 8 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: New York, United States
- Total investments: 8
- Last investment: Apr 2023
- Lead investor: 75%
- Fund size: $2.4M
- Last fund: Nov 2021
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/blue-ox-healthcare-partners
- Website: http://blueoxhcp.com

Blue Ox Healthcare Partners is a private equity investment firm that provides capital to growth-stage healthcare companies. It focuses on businesses in the middle market targeting the industry’s transformation to individuality and value-based care in healthcare services, HCIT, and medical and life sciences technologies, whose innovations,strategies, and operations are poised for growth.The firm has invested in a range of companies where its extensive healthcare industry, investment, and operational expertise can be leveraged to a company’s long-term benefit since 2009.

## Contacts

5 contacts available for Blue Ox Healthcare Partners. Shizune tracks 4 team members at Blue Ox Healthcare Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/blue-ox-healthcare-partners?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 3 | 38% |
| Biotechnology | 3 | 38% |
| Hospital | 2 | 25% |
| Health Diagnostics | 2 | 25% |
| Medical | 1 | 13% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series E | 2 | 25% |
| Series A | 1 | 13% |
| Series D | 1 | 13% |
| Series F | 1 | 13% |
| Series G | 1 | 13% |

6 stages tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Charles Kennedy | Managing Partner | 1 | — |
| Alex Rogers | Principal | 0 | — |
| Oded Levy | Managing Partner | 1 | — |
| Sheila H. Schweitzer | Co-Founder & Managing Partner | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Epic Sciences | Epic Sciences is a privately held diagnostics company committed to improving cancer management by providing easily accessible and real-time biopsy material to guide personalized medicine. Epic is founded on a powerful platform to identify and characterize rare cells including circulating tumor cells ("CTCs"). Epic is working with anumber of partners including numerous pharmaceutical companies, major cancer centers, the National Cancer Institute, and the National Institutes of Health. | $24M | Series G | Apr 14, 2023 |  |
| Gemelli Biotech | Gemelli is a biotechnology company that specializes in the microbiome, and IBS diagnostics. It strives to achieve a thriving global family of healthy individuals by unlocking the potential of the microbiome. The company is driven by its mission is to support the discovery of novel diagnostics and therapeutics for the human microbiome by bringingbiotechnology innovations to market in a fiscally responsible and socially conscious way. The company was founded in 2018 and headquartered in North Carolina, United States. | $19M | Series A | Jun 22, 2022 |  |
| Epic Sciences | Epic Sciences is a privately held diagnostics company committed to improving cancer management by providing easily accessible and real-time biopsy material to guide personalized medicine. Epic is founded on a powerful platform to identify and characterize rare cells including circulating tumor cells ("CTCs"). Epic is working with anumber of partners including numerous pharmaceutical companies, major cancer centers, the National Cancer Institute, and the National Institutes of Health. | $43M | Series F | Jun 01, 2022 |  |
| Sera Prognostics | Sera is a women’s health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera provides pivotal information during pregnancy to physicians, designed to help improve the health of their patients, and to reduce the costs of healthcare delivery. Sera has a robust pipeline of innovativediagnostic tests focused on the prediction of preterm birth risk and other complications of pregnancy. Sera’s PreTRM® Test reports to a physician the individualized risk of spontaneous premature delivery in a pregnancy, enabling earlier proactive interventions in women with higher risk. | $100M | Series E | Apr 28, 2021 |  |
| Sera Prognostics | Sera is a women’s health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera provides pivotal information during pregnancy to physicians, designed to help improve the health of their patients, and to reduce the costs of healthcare delivery. Sera has a robust pipeline of innovativediagnostic tests focused on the prediction of preterm birth risk and other complications of pregnancy. Sera’s PreTRM® Test reports to a physician the individualized risk of spontaneous premature delivery in a pregnancy, enabling earlier proactive interventions in women with higher risk. | $36M | Series D | Nov 13, 2019 |  |
| Sera Prognostics | Sera is a women’s health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera provides pivotal information during pregnancy to physicians, designed to help improve the health of their patients, and to reduce the costs of healthcare delivery. Sera has a robust pipeline of innovativediagnostic tests focused on the prediction of preterm birth risk and other complications of pregnancy. Sera’s PreTRM® Test reports to a physician the individualized risk of spontaneous premature delivery in a pregnancy, enabling earlier proactive interventions in women with higher risk. | $36M | Series D | Nov 13, 2019 |  |
| Epic Sciences | Epic Sciences is a privately held diagnostics company committed to improving cancer management by providing easily accessible and real-time biopsy material to guide personalized medicine. Epic is founded on a powerful platform to identify and characterize rare cells including circulating tumor cells ("CTCs"). Epic is working with anumber of partners including numerous pharmaceutical companies, major cancer centers, the National Cancer Institute, and the National Institutes of Health. | $52M | Series E | Sep 12, 2018 |  |
| RX Solutions | RX Solutions which helps lower-income people gain access to fixed and/or reduced cost prescription drugs. RX Solutions serves consumers by identifying Prescription Assistance Programs (“PAPs”) specific to their medication needs and then follows them throughout the process to secure the subsidies and medications. |  | Private Equity | Feb 06, 2018 |  |

8 of 8 investments shown.

## Co-investors
- [Domain Associates](https://shizune.co/investors/profile/domain-associates) — VC Fund, 4 deals together
- [LabCorp](https://shizune.co/investors/profile/laboratory-corporation-of-america) — VC Fund, 4 deals together
- Arsenal Capital Partners — VC Fund, 3 deals together
- [Catalyst Health Ventures](https://shizune.co/investors/profile/catalyst-health-ventures) — VC Fund, 2 deals together
- [Chione](https://shizune.co/investors/profile/chione) — VC Fund, 2 deals together
- [Deerfield](https://shizune.co/investors/profile/deerfield) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Krungsri Finnovate](https://shizune.co/investors/profile/krungsri-finnovate) — VC Fund
- [Munich Venture Partners](https://shizune.co/investors/profile/munich-venture-partners) — VC Fund
- [yet2Ventures](https://shizune.co/investors/profile/yet2ventures) — VC Fund

## FAQ

### What does Blue Ox Healthcare Partners invest in?

Blue Ox Healthcare Partners invests primarily in Health Care, Biotechnology and Hospital startups, most often at Series E and Series A stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Blue Ox Healthcare Partners?

Public channels for Blue Ox Healthcare Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Blue Ox Healthcare Partners?

The team at Blue Ox Healthcare Partners includes Charles Kennedy (Managing Partner), Alex Rogers (Principal) and Oded Levy (Managing Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co